These improved overall and progression-free survival have led to approval of vemurafenib by the Food and Drug Administration (FDA) on August 17, 2011, as a first line treatment in patients with BRAF-mutated unresectable or metastatic melanoma. Here, BRAF is linked to metastatic melanoma.